May 18, 2012
Ten-year data from the Southwestern Oncology Group-directed Intergroup Study 0116 confirm the benefits of adjuvant radiochemotherapy after gastric cancer resection in terms of overall survival (OS) and relapse-free survival (RFS).
May 18, 2012
For pediatric patients with tumors that have genetic aberrations in the anaplastic lymphoma kinase (ALK) gene, crizotinib is well tolerated and has antitumor activity.
May 18, 2012
Most oncologists can identify the main late or long-term effects (LEs) of chemotherapy drugs, but primary care physicians (PCPs) are less likely to be able to do so.
May 17, 2012
For patients with multiple myeloma, bisphosphonate treatment is associated with reduced pathological vertebral fractures, skeletal related events (SREs), and pain, but bisphosphonates do not appear to improve overall survival (OS), with the exception of zoledronate, which has been found to be superior to placebo and etidronate for improving OS.
May 17, 2012
For patients with V600 BRAF-mutant solid tumors, treatment with the oral BRAF inhibitor dabrafenib and the oral MEK 1/2 inhibitor trametinib is tolerated and has clinical activity in BRAF inhibitor-naive metastatic melanoma.